Charles Rosier, London UK | Partner at BTG Pactual
Charles Rosier in Supporting Health
The project was a test to find a cure for strokes that can harm the spinal cord. Charles Rosier (la page Charles Rosier) was its major investor. He invested capital in Mapreg, a Paris-based laboratory that was in the business of researching about depression, strokes and other severe issues. Being one of his healthcare projects, Charles Rosier invested in Mapreg, a pharmaceutical company led by Professor Etienne Baulieu.
Charles Rosier: Educational Background
Charles Rosier earned his first scientific Baccalaureate degree (which is similar to A-levels in the UK). In the year 1991, Charles Rosier attended his secondary education at Paris’s Fenelon Sainte-Marie. Large organisations see him to be a well-experienced banker, who is able to hold different positions in the sector.
Charles Rosier and His Career
BTG Pactual employs around 2,500 personnel from all parts of Latin America and has been in operation for more than 30 years. Charles Rosier deals with all the French-speaking markets like France, Belgium and Quebec at UBS Warburg. The appointment of this gentleman at Lehman Brothers in 1996 was his first step towards a brighter future. Eventually, he became the manager of their Debt Capital Market Division, having moved to UBS Warburg in 1997. In 1999, Charles Rosier was offered a job at Goldman Sachs (GMS). He instantly joined the team as Managing Director.
Charles Rosier’s Life
In 1991, Charles Rosier earned his scientific degree after finishing his studies at Fenelon Sainte-Marie. He was partner at BTG Pactual Bank until the year 2010. Charles Rosier was given his first employment in 1996 at Lehman Brothers and joined UBS Warburg Investment Bank prior to going to Goldman Sachs Bank where he was assigned to the finance department. He didn’t settle for a single job but took other positions in the industry while an investment banker.